- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | RACE ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| RACE ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| Do | RACE ONCOLOGY LTD: International G4 Expert Laurence Hurley Joins Race SAB | - | ASX | ||
| Mi | RACE ONCOLOGY LTD: Race Anticancer MOA Webinar | 2 | ASX | ||
| Mo | RACE ONCOLOGY LTD: Race Online Investor Briefing Invitation | 2 | ASX | ||
| Mo | RACE ONCOLOGY LTD: Date of AGM & Closing Date for Director Nominations | 3 | ASX | ||
| 03.10. | Scott Power: ASX health stocks rise; Race Oncology enjoys big week with lead drug discovery | 1 | Stockhead | ||
| 03.10. | HotCopper Highlights, Week 40: Invictus again, Metallium-Glencore hope, Race Oncology, and more | 42 | The Market Herald Australia | ||
| 02.10. | Race Oncology Identifies Breakthrough Anticancer Mechanism for Bisantrene (RCDS1) | 4 | smallcaps.com.au | ||
| 02.10. | RACE ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 02.10. | Thursday's HotCopper trends: Race Oncology, MTM, and other daily winners | Oct 2 | 1 | The Market Herald Australia | ||
| 02.10. | Why Bravura, Dateline, Orthocell, and Race Oncology shares are storming higher | 1 | The Motley Fool Australia | ||
| 02.10. | Race Oncology indentifies 'primary mechanism of action' of its lead anticancer candidate | 1 | The Market Herald Australia | ||
| 02.10. | RACE ONCOLOGY LTD: Discovery of the Anticancer Mechanism of (EE)-bisantrene | 1 | ASX | ||
| 25.09. | RACE ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 24.09. | Race Oncology's +180% month on month rally continues with fresh approval from Korean drug regulator | 5 | The Market Herald Australia | ||
| 24.09. | Why Deterra Royalties, DroneShield, Lindian, and Race Oncology shares are rising today | 66 | The Motley Fool Australia | ||
| 24.09. | RACE ONCOLOGY LTD: RC220 IND Approval from Korean MFDS | - | ASX | ||
| 23.09. | RACE ONCOLOGY LTD: Trading Policy Update | - | ASX | ||
| 18.09. | RACE ONCOLOGY LTD: Race Oncology investor briefing presentation | - | ASX | ||
| 18.09. | RACE ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,470 | -1,56 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
| EVOTEC | 6,698 | -0,86 % | Adidas, Bechtle, Bitcoin Group, Evotec, Renk, Ströer - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BIONTECH | 87,55 | -3,10 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,380 | -8,89 % | Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference | ||
| VIKING THERAPEUTICS | 29,170 | -3,62 % | Why Shares in Viking Therapeutics Surged This Week | ||
| APOGEE THERAPEUTICS | 53,23 | +0,04 % | Apogee Therapeutics sichert sich 323,3 Mio. US-Dollar durch Aktienplatzierung an der NASDAQ | ||
| INTELLIA THERAPEUTICS | 20,700 | -6,04 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 10,150 | +7,86 % | Oppenheimer senkt Kursziel für Moonlake Immunotherapeutics nach durchwachsenen Studienergebnissen | ||
| JYONG BIOTECH | 55,99 | +4,71 % | Jyong Biotech Ltd.: Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS-8 for Prostate Cancer Prevention | New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company", "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
| TOURMALINE BIO | 47,885 | +0,09 % | Novartis Pharma AG: Novartis announces commencement of tender offer to acquire Tourmaline Bio | Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis ("Purchaser"), has commenced a tender offer... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,700 | -4,19 % | UBS bestätigt Kaufempfehlung für Summit Therapeutics vor ESMO-Daten | ||
| ARCELLX | 88,99 | +0,64 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 62,00 | -4,62 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,950 | -6,89 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| 89BIO | 14,805 | -0,30 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen |
RACE ONCOLOGY LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,020 (+0,76 %) liegt der Kurs bei 2,640 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RACE ONCOLOGY LTD finden Sie auf Wallstreet Online.